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Objective: The objective of this prospective randomized phase III trial was to compare
paclitaxel plus carboplatin (PC) versus topotecan plus carboplatin and paclitaxel (TPC) in
women with suboptimal stage III (residual tumour >1 cm) or stage IV ovarian cancer to
evaluate the survival rate and toxicities.
Methods: Eligible for the study were patients aged at least 18 years old with histological/
cytological diagnosis of FIGO stages III (residual tumour P1 cm after primary surgery) –
IV epithelial ovarian cancer. Patients were randomized to iv PC on day 1, every 21 days or
iv topotecan daily for three days and PC on day 3, every 21 days.
Results: The intention to treat population was made of 326 patients in total, 170 in the PC
group and 156 in the TPC group. The life table estimates of survival probabilities at one,
three and five years were, respectively, 0.94 (95% CI: 0.88–0.97), 0.53 (95% CI: 0.44–0.62)
and 0.32 (95%CI: 0.23–0.42) in the PC group, and 0.92 (95% CI: 0.86–0.95), 0.52 (95% CI:
0.42–0.61), and 0.32(95%CI: 0.22–0.43) in the TPC group (log-rank test at 5 years: ns). The
results of the survival analysis based on Cox regression model showed no statistically sig-
nificant differences between groups (p-value: ns). The number of subjects with at least one
event with possible relationship to study medication was 151 (88.8%) in the PC group and
139 (89.1%) in the TPC group (p = ns).
Results: In the PC group, 79 patients (23.6%) experienced at least one Adverse Event (AE)
graded as severe and 16 patients (4.8%) at least one life-threatening AE, whilst in the TPChed by Elsevier Ltd.
etrico Ginecologica, Universita` degli Studi di Milano, via Commenda 12, 20122 Milano, Italy.
Bolis).
2906 E U R O P E A N J O U R N A L O F C A N C E R 4 6 ( 2 0 1 0 ) 2 9 0 5 –2 9 1 2group, the number of patients who presented at least one severe or life-threatening AE was
86 (24%) and 37 (10.3%), respectively.
Conclusion: The results of the present study show that the addition of topotecan to a stan-
dard paclitaxel/carboplatin regimen in the treatment of advanced epithelial ovarian cancer
did not result in significant advantages in terms of survival rate. A slightly worse toxicity
profile for TPC was observed.
 2010 Published by Elsevier Ltd.1. Introduction
The therapy for advanced ovarian carcinoma is maximal sur-
gical cytoreduction followed by chemotherapy.
Several trials showed that paclitaxel–carboplatin (PC) com-
bination is as effective as paclitaxel and cisplatin1–3 with a
better safety profile.
Regimens including a carboplatin plus paclitaxel have be-
come the preferred first-line therapy.
Despite the progress that has been achieved over the
years, survival rates in patients with advanced ovarian cancer
are still disappointing.4
Thus topotecan, gemcitabine, and anthracyclines have
been included into first-line regimens for advanced ovarian
cancer.5–10
According to previous experience of a salvage treatment
including carboplatin on day 3 and topotecan as a 3-day
administration,5 on 2000 started a prospective randomized
phase III trial to compare PC versus topotecan plus carboplatin
and paclitaxel (TPC) in women with suboptimal stage III
(residual tumour >1 cm) or stage IV ovarian cancer to evaluate
the survival rate and toxicities.11 In this paper we report the fi-
nal results.
2. Methods
This is an open-label, multicentre, randomized study designed
to evaluate the efficacy and the toxicities of the association PC
versus TPC in patients with FIGO stage III (residual tumour
>1 cm) – IV epithelial ovarian cancer.
Eligible for the study were patients aged at least 18 years old
with histological/cytological diagnosis of FIGO stages III (resid-
ual tumourP1 cm after primary surgery)–IV epithelial ovarian
cancer; performance Status 62 (ECOG scale); a life expectancy
of at least 3 months; presence of at least one indicator lesion
to be used for assessment of response (preferably surgery (lap-
aroscopy or laparotomy); no prior chemotherapy; laboratory
values: WBCP 3.5 · 103 ll, haemoglobinP 9.0 g/dl, neutro-
philsP 1.5 · 103 ll, plateletsP 100 · 103 ll, creatinine 6 1.5
mg/dl, or creatinine clearanceP 60 ml/min, serum bilirubin 6
2.0 mg/dl, SGOT, SGPT, and alkaline phosphatase 6 2 times the
upper limit of normal; no noteworthy ECG abnormalities.
Exclusion criteria were concomitant malignancies or pre-
vious malignancies within the last five years (excepting basal
or squamous cell carcinoma of the skin and carcinoma in situ
of the cervix); CNS and/or leptomeningeal metastases; con-
current severe medical problems unrelated to the malignancy
which would significantly limit full compliance with the
study; history of cardiac diseases, other concurrent chemo-therapy, immunotherapy, radiotherapy, or any other investi-
gational medication for the treatment of the tumour; prior
treatment with other chemotherapy regimen.
Eligible patients were randomized by phone by the coordi-
nating centre to receive either iv PC on day 1, every 21 days or
iv daily topotecan for three days and PC on day 3, every 21 days.
Study participants were stratified according to FIGO stage
of disease (stage III versus stage IV versus carcinosis) and par-
ticipating centre.
The randomization started in February 2000 and ended in
December 2003.
2.1. Group PC
Paclitaxel 175 mg/m2 was administered as a 3-h infusion fol-
lowed by carboplatin AUC 5 given as a 30-min infusion on
day 1 every 21 days for 6 cycles. Carboplatin dosage was cal-
culated according to the Cockroft and Gault formula.
2.2. Group TPC
Topotecan 1.0 mg/m2 was administered intravenously over
30 min for three days (day 1–3). Paclitaxel at a dose of 175 mg/
m2 given as a 3-h infusion followed by carboplatin AUC 5 given
as a 30-min infusion were administered on day 3 every 21 days
for 6 cycles. On day 3, the patients got the 3 drugs.
Topotecan dose was not reduced (unless the toxicity was
believed to be related to topotecan. In this case, the protocol
foresaw to reduce the dose to 0.8 mg/m2). Carboplatin and
paclitaxel were cut to AUC 4 and 150 mg/m2, respectively, if
the platelet count was <75 · 103 ll or the granulocyte count
was <1.0 · 103 ll for >7 days at nadir, despite G-CSF therapy
in the latter case.
Chemotherapy administration started within 5 weeks
since surgery.
During the 6 cycles’ period, patients with progressive dis-
ease (PD) suspended the study treatment as soon as the pro-
gression was detected.
Standard premedication included: clorfenamine maleatum
10 mg im 1 h before starting paclitaxel, cymetidin 300 mg iv,
and hydrocortisone sodium succinate 500 mg iv 30 min before
starting paclitaxel.
Centres were free to perform interval debulking surgery in
responding patients in which primary surgery was explor-
ative, laparoscopy, or laparotomy.
Second look surgery was allowed in responding patients
with negative CA 125 after 6 cycles of chemotherapy. During
second look surgery it was possible to remove residual tu-
mour in patients with partial response (PR).
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gery or indicator lesion. These lesions had to meet the criteria
for measurable or valuable disease and had to be defined by a
tumour imaging assessment (including CT or MRI scan, ultra-
sound, or chest X-ray), or physical examination. The same
diagnostic imaging method was used throughout the study
to evaluate the lesions.
Additional chemotherapy, including maintenance or con-
solidation was not allowed till the progression of the disease.
For patients who did not progress on study and completed
the treatment, the investigator conducted the post-treatment
assessments every 3 months during the first year, every 4
months during the second year, and every 6 months during
the third and the fourth year.
The study protocol did not provide any indication for sec-
ond line treatment of patients. However, the general policy of
participating centres included second-line chemotherapy
with a platinum-based compound in case of late recurrence
or progression of the disease (i.e. >12 months after first-line
treatment) and a treatment including anthracyclines in case
of early recurrence/progression.
Follow up was updated on 2007.
The study was conducted according to Good Clinical Prac-
tice guidelines and the Declaration of Helsinki and received
the approval by the Review Boards of the participating centres.
Patients had given their written informed consensus to the
study.
2.3. Statistical consideration and data analysis
The computation of the sample size considered the main end-
point: survival. The purpose of this study was to compare the
rate of overall survival at 3 years in patients receiving the
combination of PC versus TPC.
The targeted sample size for this protocol was 350
patients.
Considering an overall survival rate in the PC group of 20%
at 3 years from first diagnosis, this sample size was foreseen
to be able to identify an increase in survival rate in the TPC
group to 35% with 80% of power and alfa 0.05.
In consideration of the higher survival rate observed at 3
years in the PC group (about 40%), we have computed a post
hoc computation of the power of the study: we are able to
identify a difference in survival rate to 55% in the TPC group
with 80% of power and alfa 0.05.
2.4. Data analysis
In consideration of the availability of follow up data at the
moment of the preparation of the report of the study, 5-years
survival rates are presented in this paper for the total popula-
tion and 4-years survival rates for the analysis in strata of se-
lected variables.
The primary efficacy variable was overall survival.
The secondary efficacy variables were progression free sur-
vival and response rate.
The progression free survival was defined as the time
interval between randomization to the first documented sign
of progression.Complete response (CR) was defined as (per WHO criteria)
complete disappearance of all known measurable and evalu-
able diseases for a period of at least four weeks. Partial re-
sponse (PR) was defined as 50% or greater decrease in the
sum of the products of the greatest length and perpendicular
width of the largest measurement of all measurable lesions
for at least four weeks with no simultaneous increase in a
known lesion (>25%) or appearance of new lesions or increase
in valuable disease during this period. Progression was de-
fined as greater than 25% increase in the sum of the products
of the measurable disease, reappearance of measurable dis-
ease, clear worsening of valuable disease, appearance of any
new lesions, or significant worsening of conditions presumed
to be related to malignancy.
Toxicity was recorded according to the WHO recommen-
dations.
For efficacy analysis we considered all randomized pa-
tients who received at least one dose of study medication
(intention to treat population, ITT).
The per protocol population (PP) included all the evaluable
subjects according to the complete criteria defined in the
study protocol.
For safety analysis we considered the ITT population.
Kaplan-Meier survival estimates were plotted and the
survival probabilities in the two treatment groups were com-
pared using the log-rank test. An additional survival analysis
based on Cox regression was planned. The model included
terms for performance status: 0–1 versus 2; FIGO staging: III
versus IV; histotype: serous versus non-serous; FIGO grading:
1 versus 2/3; residual tumour: <2 cm versus 2–5 cm versus
>5 cm and/or peritoneal carcinosis; age: 650 years versus
>50 years and centre as covariates.
The percentages of patients who showed CR, PR, SD, and
PD were summarised by treatment. The response rates in
the two treatment groups were compared by means of the
chi-square test or, where appropriate, by the Fisher’s exact
test.
The number of patients experiencing adverse events and
the total number of adverse events (AE) that occurred during
the study were calculated. Differences in the number of pa-
tients with at least one AE between the two treatment groups
were tested using the chi-square test.
A summary of observed AE has been tabulated according
to common toxicity grade (NCI CTC).
The following laboratory data were analyzed by summaris-
ing the CTC grade distribution for each visit and the worst
CTC grade reported during the study: neutrophils, platelets,
haemoglobin, and leucocytes.
The number of patients who underwent supportive ther-
apy (transfusions or G-CSF) was presented for each treatment
group.3. Results
A total of 330 patients were enrolled in the study in 28 centres
in Italy.
Four patients did not present any evidence of assumption
of the study drugs. These patients were excluded from the ITT
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group, and 156 in the TPC group.
The PP population included 257 patients in total, 133 in the
PC group, and 124 in the TPC group (Fig. 1).
The distribution of study subjects according to selected
characteristics and study group is shown in Table 1.
The study groups were similar with regard to age, histo-
type, stage, grade, residual tumour, and lymph nodal status
distribution.
Since the first diagnosis, 166 patients (97.6%) in the PC
group and 148 patients (94.9%) in the TPC group underwent
surgical procedures for ovarian cancer.
In both treatment groups the most common surgical pro-
cedure was laparotomy, reported by 144 patients (86.7% of
the subjects who had a surgical procedure) in the PC group
and by 134 (90.5%) in the TPC group.
3.1. Overall survival and progression free survival
The results of the survival analysis are shown in Fig. 1. The
life table estimates of survival probabilities at one, two and
three, four and five years were, respectively, 0.94 (95% CI:
0.88–0.97), 0.71 (95% CI: 0.63–0.78), 0.53 (95% CI: 0.44–0.62),
0.41 (95% CI: 0.32–0.50), and 0.32 (95% CI: 0.23–0.42) in the PC
group, and 0.92 (95% CI: 0.86–0.95), 0.77 (95% CI: 0.69–0.84),
0.52 (95% CI: 0.42–0.61), 0.41 (95% CI: 0.31–0.51), and 0.32
(95% CI: 0.22–0.43) respectively, in the PCT group.
The comparison between the two treatment groups was
not statistically significant (log-rank test at 5 years: ns).
Analyses in strata of residual tumour, histotype, and grad-
ing showed no statistical difference on survival between both
groups, however patients with residual tumour of 1–2 cm330 patients rando
172 allocated PC
2 patients did not 
received the study 
drug
170 available for Intention to 
Treat Analysis
37 protocol 
violations
133 patients available for Per-
Protocol Analysis
CONSORT trial flow diagram for patients accrued into th
Fig. 1 – CONSORT trial flow diagramtreated with the triple schedule tended to show a higher 4-
year survival rate (0.48 versus 0.66) and subjects with carcino-
sis a lower one (0.53 versus 0.47 p ns) (Table 2).
The results of the survival analysis based on Cox regres-
sion model showed no statistically significant differences be-
tween groups (p-value: ns): the relative risk for TPC compared
to PC was 0.85 (95% CI: 0.56–1.29).
The results in the PP population were consistent with
those observed in the ITT analysis: the comparison between
the two groups was not statistically significant (log-rank test:
ns) (data not shown).
The results of the progression free survival analysis are
summarised in Figs. 2a and 2b. The comparison between
the two treatment groups was not statistically significant
(log-rank test p-value: ns). This result was confirmed for the
PP population (log-rank test p-value: ns, data not shown).
Data on objective response was available in for 137 pa-
tients in the PC and 126 in the TPC group. The results of re-
sponse rates are shown in Table 3.
No significant differences were observed between the two
treatment groups in the rate of complete or partial response
between the groups (p-value: 0.62 for CR and 0.67 for PR).
The results in the PP population were consistent with those
observed in the ITT analysis (data not shown).
3.2. Safety
The number of subjects with at least one event with possible
relationship to study medication was 151 (88.8%) in the PC
group and 139 (89.1%) in the TPC group (p = ns).
In the PC group, 79 patients (23.6%) experienced at least
one AE of severity graded as severe and 16 patients (4.8%) atmly assigned
158 allocated TPC
2 patients did not 
received the study 
drug
156 available for Intention to 
Treat Analysis
e trial.
124 patients available for Per-
Protocol Analysis
32 protocol 
violations
for patients accrued into the trial.
Table 1 – Characteristics of study patients.
PC group (No. = 170) TPC group (No. = 156)
Age in years
(mean, DS, range) 57.4 ± 10.2 (31–78) 58.7 ± 9.4 (38–75)
Histotype
Malignant serous tumours 116 (68.2%) 117 (75.0%)
Malignant mucinous tumours 4 (2.4%) 0 (0.0%)
Malignant endometroid tumours 16 (9.4%) 3 (1.9%)
Undifferentiated carcinoma 13 (7.6%) 19 (12.2%)
Malignant clear cells 11 (6.5%) 8 (5.1%)
Other 9 (5.3%) 9 (5.8%)
Not recorded 1 (0.6%) 0 (0.0%)
Grading (FIGO)
1 2 (1.2%) 0 (0.0%)
2 30 (17.6%) 28 (17.9%)
3 115 (67.6%) 108 (69.2%)
Not recorded 23 (13.5%) 20 (12.8%)
Stage (FIGO)
III 129 (75.9%) 123 (78.8%)
IV 41 (24.1%) 32 (20.5%)
Not recorded 0 (0.0%) 1 (0.6%)
Surgical procedures
No 4 (2.4%) 8 (5.1%)
Yes 166 (97.6%) 148 (94.9%)
Residual tumour (cm)
P1 and 62 20 (12.0%) 19 (12.8%)
>2 and 65 24 (14.5%) 22 (14.9%)
>5 and 610 14 (8.4%) 11 (7.4%)
>10 6 (3.6%) 5 (3.4%)
Peritoneal carcinosis 102 (61.4%) 91 (61.5%)
Site of residual tumour after primary surgery
Abdominal/pelvic 165 (97.1%) 150 (96.2%)
Hepatic 22 (12.9%) 15 (9.6%)
Lymph node 15 (8.8%) 29 (18.6%)
Pulmonary 3 (1.8%) 6 (3.8%)
Other 8 (4.7%) 8 (5.1%)
Table 2 – Four year overall survival according to study group in the total population and in strata of selected characteristics.
PC group TPC group P value
% Survival (95% confidence interval) % Survival (95% confidence interval)
Total population 41(32–50) 41(31–51) n.s.
Residual tumour (cm)
P1 to 62 48 (24–99) 66 (36–85) n.s.
>2 57(40–70) 57(37–72) n.s.
Carcinosis 53(41–64) 47(34–64) n..s.
Histotype
Serous tumour 50(39–60) 56(49–66) n.s.
Other 61(44–74) 38(19–57) n.s.
Grading
1–2 53(31–71) 58(33–77) n.s.
3 55(44–64) 52(40–63) n.s.
n.s.: not significant.
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number of patients who presented at least one severe or
life-threatening AE was 86 (24%) and 37 (10.3%), respectively.The most frequent AE are reported in Table 4.
Fatigue, anaemia, neuthopenia were significantly more frequent
in the TPC group.
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Fig. 2a – Kaplan-Meier survival plot: time to death.
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Fig. 2b – Kaplan-Meier survival plot on time to progression.
Table 3 – Response rate according to study group.
PC group TPC group P value*
No. (%) No. (%)
Complete response 67 (48.9%) 66 (52.0%)
Partial response 43 (31.4%) 43 (33.9%)
Stable disease 16 (11.7%) 6 (4.7%)
Progressive disease 11 (8.0%) 11 (8.7%) n.s.
n.s. not significant.
* Chi square heterogeneity.
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The median duration of chemotherapy was 112 days (range
22–198) in the PC group and 115 days (range 24–192) in the
TPC group (p: ns).
The number of patients with at least one course delay was
78 (49.1%) in the PC group and 76 (53.1%) in the TPC group (p:
ns).
The number of patients with at least one paclitaxel dose
reduction was 18 (11.3%) in the PC group and 40 (28.0%) inthe TPC group (p: <0.001) and those with at least one carbo-
platin dose reduction was respectively 16 (10.1%) and 44
(30.8%) (p: <0.001).
Two patients (1.4%) at cycle 2 and 1 (0.8%) at cycle 3 re-
quired topotecan dose reduction.
The number of patients who completed six treatment cy-
cles was 139 (82.2%) in the PC group and 121 (77.6%) in the
TPC group (p: 0.29).
3.4. Supportive therapy
The number of patients who received transfusions was 16
(11.6%) in the PC group and 32 (26.9%) in the TPC group (p:
0.002).
The number of patients who received G-CSF at the end of
treatment was 10 (7.2%) in the PC group and 30 (25.2%) in
the TPC group (p: <0.001).
4. Discussion
The primary objective of this study was to evaluate survival in
the two following treatment regimens: PC versus TPC in
patients with sub optimally-resected stage III or IV ovarian
cancer.
The general results show that there were no statistically
significant differences between the two treatment regimens
in survival rate. Moreover, the comparison between both
groups in terms of time to progression and response rate
did not show any statistically significant difference.
With regard to safety and tolerability, the rate of drug-re-
lated adverse events was similar in the two groups, whilst
the risk of drug-related serious adverse events was higher in
the group of patients receiving additional topotecan.
The risk of anaemia and leucopenia was higher in the TPC
than in the PC group and the percentage of patients requiring
transfusions or supportive G-CSF therapy was lower in the PC
group than in the TPC group.
The results of this study should be discussed in compari-
son with published data.
Several randomized clinical trials have tested the role of
triple cytotoxic therapy for advanced ovarian cancer in com-
parison with standard treatment with carboplatin or cisplatin
plus paclitaxel. Triple schedules included anthracycline, gem-
citabine, and topotecan. In general no differences emerged.12
In particular, some studies randomized clinical trials and
one phase II study have included topotecan in the triple
schedule.
Table 4 (continued)
Paclitaxel/
carboplatin
(N = 170)
Paclitaxel/
carboplatin/topotecan
(n = 156)
Leucocytes
0 (P3.5 · 103 ul) 71 (41.8%) 51 (32.7%)
1 (P3 e < 3.5 · 103 ul) 39 (22.9%) 27 (17.3%)
2 (P2 e < 3 · 103 ul) 56 (32.9%) 61 (39.1%)
3 (P1 e < 2 · 103 ul) 4 (2.4%) 17 (10.9%)
P value 0.004
Neutrophils
0 (P2 · 103 ul) 24 (14.1%) 29 (18.6%)
1 (P1.5 e < 2 · 103 ul) 35 (20.6%) 23 (14.7%)
2 (P1 e < 1.5 · 103 ul) 71 (41.8%) 42 (26.9%)
3 (P0.5 e < 1 · 103 ul) 31 (18.2%) 52 (33.3%)
4 (<0.5 · 103 ul) 9 (5.3%) 10 (6.4%)
P value 0.004
Note: only the event with the maximum toxicity grade was con-
sidered for each patient and AE.
Table 4 – Summary of patients with adverse events by
common toxicity grade.
Paclitaxel/
carboplatin
(N = 170)
Paclitaxel/
carboplatin/topotecan
(n = 156)
Allergy
Mild 8 (4.71%) 8 (5.13%)
Moderate 1 (0.59%) 4 (2.56%)
Severe 1 (0.59%) 5 (3.21%)
Life threatening 1 (0.59%) 0 (0.00%)
Not indicated 0 (0.00%) 1 (0.64%)
P value ns
Anorexia
Mild 2 (1.18%) 1 (0.64%)
Moderate 1 (0.59%) 0 (0.00%)
P value n.s.
Arthralgia
Mild 4 (2.35%) 5 (3.21%)
Moderate 4 (2.35%) 2 (1.28%)
P value n.s.
Fatigue
Mild 2 (1.18%) 8 (5.13%)
Moderate 2 (1.18%) 0 (0.00%)
Severe 0 (0.00%) 1 (0.64%)
Not indicated 1 (0.59%) 0 (0.00%)
P value 0.05
Febrile neutropenia
Mild 0 (0.00%) 1 (0.64%)
Life threatening 0 (0.00%) 1 (0.64%)
P value n.s.
Nausea
Mild 28 (16.47%) 31 (19.87%)
Moderate 16 (9.41%) 17 (10.90%)
Severe 1 (0.59%) 3 (1.92%)
P value n.s.
Neurotoxicity
Mild 51 (30.00%) 47 (30.13%)
Moderate 6 (3.53%) 3 (1.92%)
Severe 2 (1.18%) 2 (1.28%)
Not indicated 0 (0.00%) 1 (0.64%)
P value n.s.
Mucositis
Mild 0 (0.00%) 2 (1.28%)
Moderate 1 (0.59%) 1 (0.64%)
P value n.s.
Vomiting
Mild 7 (4.12%) 9 (5.77%)
Moderate 8 (4.71%) 16 (10.26%)
Severe 1 (0.59%) 3 (1.92%)
Life threatening 0 (0.00%) 1 (0.64%)
P value n.s.
Thrombosis
Severe 0 (0.00%) 1 (0.64%)
P value n.s.
Haemoglobin
0 (>10 g/dL) 102 (60.0%) 50 (32.1%)
1 (=10 g/dL) 1 (0.6%) 3 (1.9%)
2 (P8 e < 10 g/dL) 64 (37.6%) 93 (59.6%)
3 (P6.5 < 8 g/dL) 2 (1.2%) 10 (6.4%)
4 (<6.5 g/dL) 1 (0.6%) 0 (0.0%)
P value <0.01
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study, the patients who received PC plus topotecan reported
a 3-weeks decrement in median progression free survival in
comparison with patients receiving standard CP treatment.10
Pfisterer et al.9 (2006) conducted a randomized trial includ-
ing 1308 patients with stage IIB–IV ovarian cancer. These pa-
tients were randomized to receive six cycles of paclitaxel
and carboplatin followed by either four cycles of topotecan
or surveillance on a 3-week per cycle schedule. The median
survival was 43.1 months for the topotecan group and 44.5
months for the surveillance one.
Further, in a small phase II study 343 patients with ad-
vanced ovarian cancer and >1 cm residual disease were trea-
ted with sequential carpoblatin (AUC 5 days 1 and 22)
paclitaxel (1.75 mg m()2) days 43 and 64) and topotecan
1.5 mg m()2) daily for 5 days. The best overall response was
77% and the median survival was 22.2 months.13
The standard dose of topotecan as monotherapy in first or
second line therapy for ovarian cancer is 1.5 mg/m2 over 5
days. In the Gynaecologic Cancer InterGroup study, topotecan
was given at in the dose of 1.25 mg/m2. In the present series
topotecan was given at the dose of 1.0 mg/m2 over 3 days
and the effective given dose was lower.
Delivery of the third drug in an adequate dosage is diffi-
cult.12 Further, concomitant delivery of topotecan, paclitaxel
with a platinum compound has been shown feasible with cis-
platin,14 but not with carboplatin.
Earlier phase I studies including topotecan and cisplatin
suggested that myelosuppression was lower if cisplatin was
given on day 5 rather than day 1.12
In this study carboplatin was given on day 3.
It has been suggested that more aggressive therapy may
have greater impact in patients with small volume residual
disease. Along this line, in the Gynaecologic Cancer Inter-
Group analysis, the TPC schedule showed a, not statistically
significant, better survival rate than PC one in patients with
microscopic residual tumour, but not with residual tumour
61 cm or >1 cm.10
2912 E U R O P E A N J O U R N A L O F C A N C E R 4 6 ( 2 0 1 0 ) 2 9 0 5 –2 9 1 2We have analyzed overall survival rates in the strata of
residual tumour, histotype and grading. No statistical differ-
ence emerged, but patients with residual tumour of 1–2 cm
treated with the triple schedules had a higher, not significant,
4-year survival rate (0.66 versus 0.48).
In this analysis also progression free survival rates were
similar in the two groups. In this study second look surgery
was allowed. It has been shown that second surgical assess-
ment of small-volume disease may change the determination
of time to progression,15 but in this randomized trial second
look surgery was performed in both the groups in a similar
frequency.
In conclusion, the results of the present study show that
the addition of topotecan to a standard paclitaxel/carboplatin
regimen in the treatment of advanced epithelial ovarian can-
cer did not result in significant advantages in terms of sur-
vival rate, time to progression and response. These findings
are in general agreement with the result of the large data
set of the Gynaecologic Cancer InterGroup study. A slightly
worse toxicity profile for TPC as well as a more frequent need
for more G-CSF was observed.
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